Abstract: Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and R1 through R5 are as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.

Abstract: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.

Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Abstract: Methods and apparatus for operating on images are described, in particular methods and apparatus for interest point detection and/or description working under different scales and with different rotations, e.g. for scale-invariant and rotation-invariant interest point detection and/or description. The present invention can provide improved or alternative apparatus and methods for matching interest points either in the same image or in a different image. The present invention can provide alternative or improved software for implementing any of the methods of the invention. The present invention can provide alternative or improved data structures created by multiple filtering operations to generate a plurality of filtered images as well as data structures for storing the filtered images themselves, e.g. as stored in memory or transmitted through a network. The present invention can provide alternative or improved data structures including descriptors of interest points in images, e.g.

Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.

Abstract: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.

Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.

Abstract: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.

Abstract: The present invention relates, in general, to sheet material forming technology and the forming of structures there from. The invention relates to incremental forming of sheet material (1) with localised heating (5) and more particularly to a system and method for incrementally forming a sheet blank (1) that is at the same time heated by a dynamically moving heating source (5). This dynamic and localised heating locally changes the mechanical properties of the sheet material (1), thus facilitating the forming process.

Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.

Abstract: A protective helmet is described comprising: an outer layer (1); an inner layer (5) for contact with a head of a wearer; and an intermediate layer (3, 4) comprising an anisotropic cellular material comprising cells having cell walls, the anisotropic cellular material having a relatively low resistance against deformation resulting from tangential forces on the helmet. The anisotropic material can be a foam or honeycomb material. The foam is preferably a closed cell foam. The helmet allows tangential impacts to the helmet which cause less rotational acceleration or deceleration of the head of the wearer compared to helmets using isotropic foams while still absorbing a significant amount of rotational energy.

Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

Abstract: The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes.

Abstract: Present invention involves a seal means suitable to replace the classic seals. For instance the seal means of present invention can be a liquid seal ring (7) to replace the classic rubber seal rings. Such is liquid O-ring can be adapted to resists the actuation pressure relying on surface tension forces. Such liquid O-rings can also be linked in series, hereby increasing the maximum seal pressure. In a preferred embodiment the seal means of present invention comprises two major components, a surface tension seal (7) and a pressure divider (4). The pressure divider will comprise a system that generates a pressure drop. Such pressure divider can be located before the surface tension seal and perform the first pressure drop. The combination of these two systems has the advantage that the surface tension seal is able to reduce the leakage to zero or essentially zero and that the pressure divider is able to perform a large pressure drop.

Abstract: The compound 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2 -(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, together with the salts and solvates thereof. Also provided are compositions comprising this compound and pharmaceutically acceptable carriers, as well as the use of such compositions in the treatment or prophylaxis of viral infections.

Abstract: The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one compound having the general formula (A): wherein U is N or C; X is selected from C1-C10 alkylene, C2-10 alkenylene or C2-10 alkynylene, where each may include one or more intrachain heteroatoms selected from O, S, or NR11, provided any such heteroatom is not adjacent to the N in the ring; R3 is selected from aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N(R10)—, or heterocycle, where each said substituent is optionally substituted with at least one R17, provided that for cycloalkenyl the double bond is not adjacent to a nitrogen; and the other substituents are described in the specification.

Abstract: The present invention clearly demonstrates that vWF-collagen interaction, via the A3 domain of vWF, plays an important role in acute platelet-dependent arterial thrombus formation and that blocking the A3 domain in a vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, an antibody or an antigen recognizing fragment thereof binding specifically to the A3 domain of vWF or an epitope thereof can be used for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to for the prevention of acute arterial thrombotic syndromes.

Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.